CN101466667A - 作为g蛋白偶联受体（gpr119）激动剂的氮杂环丁烷衍生物 - Google Patents

作为g蛋白偶联受体（gpr119）激动剂的氮杂环丁烷衍生物 Download PDF

Info

Publication number
CN101466667A
CN101466667A CNA2007800217539A CN200780021753A CN101466667A CN 101466667 A CN101466667 A CN 101466667A CN A2007800217539 A CNA2007800217539 A CN A2007800217539A CN 200780021753 A CN200780021753 A CN 200780021753A CN 101466667 A CN101466667 A CN 101466667A
Authority
CN
China
Prior art keywords
compound
alkyl
acceptable salt
pharmacy acceptable
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800217539A
Other languages
English (en)
Chinese (zh)
Inventor
M·C·T·法伊夫
W·加特赖尔
C·M·拉沙米熊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of CN101466667A publication Critical patent/CN101466667A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2007800217539A 2006-04-11 2007-04-11 作为g蛋白偶联受体（gpr119）激动剂的氮杂环丁烷衍生物 Pending CN101466667A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0607196.3A GB0607196D0 (en) 2006-04-11 2006-04-11 G-protein coupled receptor agonists
GB0607196.3 2006-04-11

Publications (1)

Publication Number Publication Date
CN101466667A true CN101466667A (zh) 2009-06-24

Family

ID=36539676

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800217539A Pending CN101466667A (zh) 2006-04-11 2007-04-11 作为g蛋白偶联受体（gpr119）激动剂的氮杂环丁烷衍生物

Country Status (13)

Country Link
US (1) US20090281076A1 (US07365084-20080429-C00036.png)
EP (1) EP2010485B1 (US07365084-20080429-C00036.png)
JP (1) JP2009533410A (US07365084-20080429-C00036.png)
KR (1) KR20080109085A (US07365084-20080429-C00036.png)
CN (1) CN101466667A (US07365084-20080429-C00036.png)
AU (1) AU2007235674A1 (US07365084-20080429-C00036.png)
BR (1) BRPI0709953A2 (US07365084-20080429-C00036.png)
CA (1) CA2648687A1 (US07365084-20080429-C00036.png)
GB (1) GB0607196D0 (US07365084-20080429-C00036.png)
MX (1) MX2008012946A (US07365084-20080429-C00036.png)
NO (1) NO20084364L (US07365084-20080429-C00036.png)
NZ (1) NZ571962A (US07365084-20080429-C00036.png)
WO (1) WO2007116230A1 (US07365084-20080429-C00036.png)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104725355A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 一种含烟酸酰胺和哌啶结构ptp1b抑制剂及其用途
CN104725354A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺和哌啶结构化合物及其用途
CN104788424A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
BRPI0817211A2 (pt) 2007-09-20 2017-05-16 Irm Llc composto composições como moduladores da atividade de gpr119
GB0720389D0 (en) * 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) * 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2009105715A1 (en) * 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
MX2010009203A (es) * 2008-02-22 2010-11-10 Irm Llc Compuestos y composiciones como modulares de la actividad de gpr119.
WO2009126535A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
MX2011000664A (es) 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
WO2010059393A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Serotonin receptor modulators
US8575364B2 (en) 2008-10-30 2013-11-05 Janssen Pharmaceutica Nv Modulators of serotonin receptor
US8742117B2 (en) 2008-12-24 2014-06-03 Cadila Healthcare Limited Oxime derivatives
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
AR077214A1 (es) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
TW201111361A (en) 2009-06-24 2011-04-01 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
US8575168B2 (en) * 2009-10-09 2013-11-05 Irm Llc Compounds and compositions as modulators of GPR119 activity
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
BR112013006272A2 (pt) 2010-09-17 2019-09-24 Purdue Pharma Lp compostos de piridina e seus usos
AP2013006812A0 (en) 2010-10-08 2013-04-30 Cadila Healthcare Ltd Novel GRP 119 agonists
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
EP2643311A1 (en) 2010-11-26 2013-10-02 Lupin Limited Bicyclic gpr119 modulators
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AR091739A1 (es) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Composiciones y metodos para reducir el riesgo cardiometabolico

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130309A (en) * 1991-04-12 1992-07-14 A. H. Robins Company, Incorporated Aryloxy and aryloxyalklazetidines as antiarrhythmic and anticonvulsant agents
SK101199A3 (en) * 1997-02-10 2000-10-09 Pfizer Prod Inc 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines, their use and pharmaceutical compositions based thereupon
AR041786A1 (es) * 2002-03-15 2005-06-01 Novartis Ag Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
SE0301368D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
CN1898235A (zh) * 2003-12-24 2007-01-17 普罗西迪恩有限公司 作为gpcr受体激动剂的杂环衍生物
CN101083992A (zh) * 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
AP2007004047A0 (en) * 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2006113704A2 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104725355A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 一种含烟酸酰胺和哌啶结构ptp1b抑制剂及其用途
CN104725354A (zh) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺和哌啶结构化合物及其用途
CN104788424A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途
CN106883211A (zh) * 2015-03-12 2017-06-23 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺和哌啶结构化合物及其用途

Also Published As

Publication number Publication date
MX2008012946A (es) 2008-11-28
KR20080109085A (ko) 2008-12-16
NZ571962A (en) 2011-07-29
WO2007116230A8 (en) 2007-12-27
BRPI0709953A2 (pt) 2011-08-02
EP2010485A1 (en) 2009-01-07
US20090281076A1 (en) 2009-11-12
NO20084364L (no) 2008-10-31
GB0607196D0 (en) 2006-05-17
AU2007235674A1 (en) 2007-10-18
WO2007116230A1 (en) 2007-10-18
EP2010485B1 (en) 2012-10-17
JP2009533410A (ja) 2009-09-17
CA2648687A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
CN101466667A (zh) 作为g蛋白偶联受体（gpr119）激动剂的氮杂环丁烷衍生物
EP2321308B9 (en) Piperidine gpcr agonists
JP4916452B2 (ja) Ｇｐｃｒ作動薬としてのピリジン、ピリミジン、およびピラジンの誘導体
EP2114935B1 (en) Piperidine gpcr agonists
CN102131778A (zh) 杂环gpcr激动剂
CN102089298A (zh) 杂环gpcr激动剂
EP2318399B1 (en) Piperidinyl gpcr agonists
CN101123964B (zh) G蛋白偶联受体(gpr116)激动剂以及包含它的药物组合物
US20100048625A1 (en) Piperidine gpcr agonists
CN101627035A (zh) 哌啶gpcr激动剂
CN101627036A (zh) 哌啶gpcr激动剂
CN101115740A (zh) 作为代谢调节剂的经取代吡啶基和嘧啶基衍生物和相关疾病的治疗
CN102395584A (zh) 用于代谢疾病治疗的化合物
CN101460493A (zh) 杂环g蛋白偶联受体激动剂
ES2369944T3 (es) Agonistas de gpcr piperidínicos.
CN101253151A (zh) Gpcr激动剂
CN101627037A (zh) 哌啶gpcr激动剂
CN101622249A (zh) 哌啶gpcr激动剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20090624